G
Giuseppe Giaccone
Researcher at VU University Medical Center
Publications - 349
Citations - 27209
Giuseppe Giaccone is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 83, co-authored 323 publications receiving 25916 citations. Previous affiliations of Giuseppe Giaccone include VU University Amsterdam.
Papers
More filters
Journal ArticleDOI
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Rui Ping Dong,José Baselga +19 more
TL;DR: Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.
Journal ArticleDOI
Targeting the dynamic HSP90 complex in cancer
TL;DR: The molecular chaperone heat shock protein 90 (HSP90) has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90.
Journal ArticleDOI
Cell Death Independent of Caspases: A Review
TL;DR: The various models of PCD and their death pathways at molecular and organelle level are reviewed and the relevance of the growing knowledge of caspase-independent cell death pathways for cancer is discussed.
Journal ArticleDOI
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
Daphne W. Bell,Thomas J. Lynch,Sara M. Haserlat,Patricia L. Harris,Ross A. Okimoto,Brian W. Brannigan,Dennis C. Sgroi,Beth Muir,Markus J. Riemenschneider,Renee Iacona,Annetta D. Krebs,David H. Johnson,Giuseppe Giaccone,Roy S. Herbst,Christian Manegold,Masahiro Fukuoka,Mark G. Kris,José Baselga,Judith S. Ochs,Daniel A. Haber +19 more
TL;DR: EGFR mutations and, to a lesser extent, amplification appear to identify distinct subsets of NSCLC with an increased response to gefitinib, and the combination of gefithinib with chemotherapy does not improve survival in patients with these molecular markers.
Journal ArticleDOI
Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Roldano Fossati,Valter Torri,Lucio Crinò,Giuseppe Giaccone,Giovanni Silvano,Massimo F. Martelli,M. Clerici,Francesco Cognetti,Maurizio Tonato +9 more
TL;DR: This randomized trial failed to prospectively confirm a statistically significant role for adjuvant chemotherapy in completely resected NSCLC and given the poor compliance with the MVP regimen used in this study, future studies should explore more effective treatments.